




**B · M O R E**

FUNDING PSILOCYBIN:  
MAKING RECOVERY A REALITY

**Introductory Overview**



## Funding Psilocybin: Making Recovery a Reality

B.More, a non-profit lifescience company, backing clinical trial research for regulatory approval of psychedelic medicines to treat Alcohol Use Disorder (AUD) and other addictions

Reduce heaving  
drinking days

Improve  
alcohol  
abstinence

Provide  
long-lasting  
effect

Offer  
benefits over  
existing  
treatments



### Blazing the path

B.More is blazing the path for regulatory approval of psychedelic medicines to treat substance abuse




### Committed to Better

We are committed to finding better solutions for treating alcoholism and other addictions to help those who have found little success with more traditional programs.



### Support Psilocybin

Our research, along with Usona and clinical trials at NYU, aims to support the approval of psilocybin as a prescription medication with the FDA.



## Why B.More?

B.More is named after Brett Moore, who died of a drug overdose 50 years ago and was the brother of our co-founder, Claudia Turnbull. To keep his name alive and help others suffering from addiction disorders, B.More came into being.

B.More is a 501(c)(3) non-profit lifescience company studying psilocybin, a classic psychedelic, to treat patients suffering from Alcohol Use Disorder (AUD) and who may have been unsuccessful with more traditional drug and treatment programs.

# How We Are Bringing This Effective Treatment to Market




## Identify the Opportunity

Psilocybin treatment for AUD to substance abuse represents an opportunity to address a massive source of human suffering. In 2019, 1.5 mm individuals, in the US, sought treatment, with 70% relapsing within the first year.\*



## Conduct Research


Following a successful pre-IND meeting with the FDA, we know the pathway to bring psilocybin to the market to treat AUD. For the next phase of development, we will conduct a definitive clinical trial to assess the efficacy of psilocybin in treating problematic drinking.



## Join the Movement

This is a unique opportunity to support the approval of psilocybin as an FDA-approved medicine to provide an effective treatment to the millions of people suffering from AUD. **Partner with us today to bring psilocybin to market, and we will change the world tomorrow.**

# B. More and Carey Turnbull: Over a decade of driving clinical research and progress in neurotransformational medicines




Since 2010, Carey Turnbull has contributed as a fund raiser and individual donor over \$29 MM to Psychedelic Research

# Alcohol Use Disorder: amongst the most prevalent and disabling psychiatric disorders worldwide

It is a significant burden for individuals, families and society at large

- Often have chronic, relapsing course
- Modestly effective interventions include:
  - Mutual help
  - Several psychosocial treatments
  - Pharmacotherapies
- No one approach works for everyone

## AUD-Attributed Facts



## Other Areas of Distress & Burden



### FINANCIAL

- Work obligations frequently neglected resulting in unemployment
- Maintaining alcohol consumption increases tolerance at a high cost



### FAMILY

- Children often experience neglect, physical and mental abuse from intoxicated parents
- Early childhood exposure to alcohol may increase risk of future alcohol abuse
- Excessive prenatal exposure to alcohol increases the risk for a range of physical, cognitive and mental development issues




### SOCIAL

- Continuing to drink even when it causes problems with friends and family
- AUD often causes personality changes that include withdrawn affect, loss of interest, and violence

Source:

1. US National Institute on Alcohol Abuse and Alcoholism
2. Alcohol in Europe, a Public Health Perspective, European Commission 2006
3. CDC Alcohol and Public Health, 2010 data

# Existing therapies do not provide adequate efficacy




The effects of Naltrexone (Vivitrol®) on alcohol consumption are minimal

Treatment Dose	1	2	3	4	5	6
No. of Patients						
Placebo	209	194	169	160	142	134
Naltrexone						
190 mg	210	187	169	156	144	137
380 mg	205	186	161	147	139	130

Source: Garbutt, J. C. et al. JAMA 2005;293:1617-1625


# SYNP-101: Building on promising research at leading universities

- SYNP-101 is a synthetic form of the naturally occurring compound, psilocybin, found in at least 200 species of mushrooms
- For over a decade, thousands of cluster headache sufferers have self-medicated using psilocybin with exceptional results
- Psilocybin has been shown to be safe when administered in a therapeutic setting




Psilocybin Proof-of-concept study with 10 subjects demonstrated treatment effect and limited side effect.

*Bogenschutz et al, Journal of Psychopharmacology (2015)*



Interim results from double-blind RCT (n>100) showing similar promising results from the POC.


*Bogenschutz Presentation, American Academy of Addiction Psychiatry 2017*



\*p<0.05  
\*\*p<0.01



# B.More has established collaborations with leading institutions and stakeholders in Alcohol Use Disorder and psychedelic research



# Experience that knows how to deliver value



**Carey Turnbull**  
FOUNDER / CEO

10+ years Investment/  
Philanthropy in Psychedelic  
Medicine



**Kathleen Monroe**

COO  
20+ years Pharmaceutical  
Project Management



**Judy Ashworth, MD**

Chief Medical Officer  
Clinical & Regulatory Strategy  
20+ years Analgesic &  
CNS Drug Development



**Shayne Gad, PhD, DABT**

Pharmacology & Toxicology  
40+ years Toxicology &  
Pharmacology



**Stephan Loose, MBA**

Chief Commercial Officer  
15+ years Pharmaceutical  
Commercialization & Business  
Development



**Jeanne Bonelle**

Chief Scientific Officer  
40+ years in Quality Assurance  
and CMC development



**Tom Huijbers**

Regulatory Affairs, R&D  
20+ years Regulatory  
Pharmaceutical Strategist



**Ryan Lanier, PhD**

Clinical Scientist  
20+ years Pre-Clinical & Clinical  
Development of CNS Drugs

# Leading experts as: Scientific Advisors



## Michael Bogenschutz, MD

NYU Langone's Department of Psychiatry

Professor, Department of Psychiatry at NYU Grossman School of Medicine, Addiction & Social Anxiety Disorders



## Jack Henningfield, PhD

Regulatory Strategy

- Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates
- Adjunct Professor, Behavioral Biology, Medical School's Department of Psychiatry and Behavioral Sciences



## Sarah E. Mennenga, PhD

NYU Langone's Department of Psychiatry

Research Assistant Professor, Department of Psychiatry, NYU Grossman School of Medicine

NYU Clinical Team with Dr Bogenschutz



# And Our Board of Directors



## Alan Fournier

- Founder, Pennant Investors, LLC
- Founder, The Fournier Family Foundation



## T. Cody Swift

- AMFT, M.A. Existential-Phenomenological Counseling Psychology
- Executive Director, Riverstyx Foundation



## Claudia Turnbull

- Investigator, Johns Hopkins Center for Psychedelic and Consciousness Research
- Board Member, Heffter Research Institute
- Board Member, Ceruvia Lifesciences
- Board of Trustees, College of the Atlantic
- Co-founder, B.More

**Together, we can change lives.**

**We believe Psilocybin is the answer to AUD, other substance abuse, and addiction**

### **Provide a Solution**

Today, an **effective and sustaining treatment for AUD does not exist**

### **Relieve People Suffering from AUD**

Each year **450,000 individuals experience a relapse** from a treatment plan and fall into their addiction once again

### **Effect Positive Social Change**

Addiction costs the USA **\$250 billion per year** in loss of workplace activity, criminal justice expenses and damages, and healthcare expenses

**JOIN THE MOVEMENT.**

**Bring psychedelic medicine to the market as an efficient way to treat alcoholism**

**THANK YOU**



**B · M · O · R · E**

FUNDING PSILOCYBIN:  
MAKING RECOVERY A REALITY

